Vaccine Administration is a pivotal aspect of public health strategies aimed at preventing infectious diseases and safeguarding population health. It encompasses the process of delivering vaccines to individuals through various routes, such as intramuscular injection, subcutaneous injection, oral ingestion, or nasal spray. The goal of vaccine administration is to ensure the safe, efficient, and effective delivery of vaccines to induce immunity against specific pathogens. Vaccine administration begins with the selection of appropriate vaccines based on factors such as age, risk factors, and disease prevalence. Healthcare providers are responsible for administering vaccines according to recommended schedules established by public health authorities. Proper storage, handling, and preparation of vaccines are essential to maintain their stability and potency, ensuring optimal vaccine efficacy.
The choice of administration route depends on several factors, including the type of vaccine, the age of the recipient, and the desired immune response. For example, many vaccines are administered via intramuscular injection to facilitate rapid uptake by the immune system and induce a robust immune response. Subcutaneous injection is another common route, particularly for vaccines that require slower release into the bloodstream. In addition to traditional injection methods, alternative vaccine delivery technologies are emerging, such as microneedle patches, needle-free injection devices, and novel delivery platforms. These technologies offer advantages such as painless administration, reduced risk of needlestick injuries, and potential for self-administration, which can improve vaccine acceptance and coverage rates.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States